2008 Vol. 35 No. 04
2008, 35(04): 229-232.
DOI: 10.3971/j.issn.1000-8578.2906
Abstract：
Objecuiwe To consuruct a non-replicating vaccinia virus expressing HPV16 L1,L2E7 proteins as a candidate vaccine for cervical cancer. Methods Using vaccinia virus vector,we generated a strain of non-replicating recombinant vaccinia virus vaccine expressing HPV16 L1,L2E7 proteins by homologous recombination and identified by PCR and Western blot. Results We demonstrated that the L1,L2E7 gene of HPV16 were integrated into vaccinia genosome and could express L1,L2E7 protein stably when infected the CEF using PCR and Western blot assay. Conclusion NTVJL1/ L2 E7 can express L1, L2 E7 protein of HPV16 and can be taken as a candidate vaccine for HPV16 associated diseases.
Objecuiwe To consuruct a non-replicating vaccinia virus expressing HPV16 L1,L2E7 proteins as a candidate vaccine for cervical cancer. Methods Using vaccinia virus vector,we generated a strain of non-replicating recombinant vaccinia virus vaccine expressing HPV16 L1,L2E7 proteins by homologous recombination and identified by PCR and Western blot. Results We demonstrated that the L1,L2E7 gene of HPV16 were integrated into vaccinia genosome and could express L1,L2E7 protein stably when infected the CEF using PCR and Western blot assay. Conclusion NTVJL1/ L2 E7 can express L1, L2 E7 protein of HPV16 and can be taken as a candidate vaccine for HPV16 associated diseases.
2008, 35(04): 233-235.
DOI: 10.3971/j.issn.1000-8578.569
Abstract：
Objective To investigate effects of cyclooxygenase-2 selective inhibitor on the expression of VEGF-C and bcl-2 mRNA in human prostate cancer PC-3 cell lines,and study the anticancer mechanism of COX-2 selective inhibitor. Methods The PC-3 cells were divided to four groups:Test groups(The cells were treated with celecoxib at different concentrations-10 μmol/L,20 μmol/L,40 μmol/L) and control group(celecoxib was not used),detected the expression of VEGF-C and bcl-2 mRNA in the four groups by RT-PCR method. Results There were no statistical difference of the VEGF2C/ GAPDH and bcl22/ GAPDH value between 10 μmol/ L celecoxib group and cont rol group ( P > 0. 05) ;VEGF2C/ GAP2 DH value in 20μmol/ L and 40μmol/ L celecoxib groups were 0. 370 ±0. 063 and 0. 263 ±0. 062 respectively, bcl22/ GAPDH value in both the groups above were 0. 339 ±0. 047 and 0. 272 ±0. 042 respectively, both the value above in the two groups decreased significantly compared with cont rol group ( P <0. 01) . Conclusion Celecoxib maybe plays it s antitumor effect by inhibiting the expression of VEGF2C and bcl22 mRNA in prostate cancer PC23 cell lines.
Objective To investigate effects of cyclooxygenase-2 selective inhibitor on the expression of VEGF-C and bcl-2 mRNA in human prostate cancer PC-3 cell lines,and study the anticancer mechanism of COX-2 selective inhibitor. Methods The PC-3 cells were divided to four groups:Test groups(The cells were treated with celecoxib at different concentrations-10 μmol/L,20 μmol/L,40 μmol/L) and control group(celecoxib was not used),detected the expression of VEGF-C and bcl-2 mRNA in the four groups by RT-PCR method. Results There were no statistical difference of the VEGF2C/ GAPDH and bcl22/ GAPDH value between 10 μmol/ L celecoxib group and cont rol group ( P > 0. 05) ;VEGF2C/ GAP2 DH value in 20μmol/ L and 40μmol/ L celecoxib groups were 0. 370 ±0. 063 and 0. 263 ±0. 062 respectively, bcl22/ GAPDH value in both the groups above were 0. 339 ±0. 047 and 0. 272 ±0. 042 respectively, both the value above in the two groups decreased significantly compared with cont rol group ( P <0. 01) . Conclusion Celecoxib maybe plays it s antitumor effect by inhibiting the expression of VEGF2C and bcl22 mRNA in prostate cancer PC23 cell lines.
2008, 35(04): 236-239.
DOI: 10.3971/j.issn.1000-8578.1399
Abstract：
Objective This study investigated the inhibitory effects of 15-hydroxyprostaglandin dehydrogenase gene(PGDH) on the proliferation of SW480 colorectal cancer cells. Methods Recombinant plasmid pcDNA3.1-PGDH with PGDH open reading frame was constructed.The SW480 cells were transfected with either pcDNA3.1 or pcDNA3.1-PGDH using LipofectaminTM 2000.The cell growth kinetics and the ability of proliferation in vitro were detected by MTT and colony formation assay.Flow cytometry was applied to analyze the cell cycle. The expression of PGDH protein and the variation of p53 and p21 were detected in SW480 cells were examined by Western blot . Results The plasmid of pcDNA 3. 12 PGDH was successfully established. After being t ransfected with this gene, the growth velocity of these t ransfected cells was significantly slower than the parental cell line. Colony formation activity of SW480/pcDNA 3. 12PGDH was 16 % while that of the cont rol cell was 58 % in six well plate ( P < 0. 05) . The activity of anchorage2independent proliferation of SW480/ pcDNA 3. 1 PGDH was lower than that of SW480/ pcDNA 3. 1 in soft agar. Otherwise, the expression of p53 and p21 were higher than cont rol. Conclusion PGDH could reduce the abilities of proliferation and of anchorage2independent proliferation of SW480 cells which is through p53 pathway possibility.
Objective This study investigated the inhibitory effects of 15-hydroxyprostaglandin dehydrogenase gene(PGDH) on the proliferation of SW480 colorectal cancer cells. Methods Recombinant plasmid pcDNA3.1-PGDH with PGDH open reading frame was constructed.The SW480 cells were transfected with either pcDNA3.1 or pcDNA3.1-PGDH using LipofectaminTM 2000.The cell growth kinetics and the ability of proliferation in vitro were detected by MTT and colony formation assay.Flow cytometry was applied to analyze the cell cycle. The expression of PGDH protein and the variation of p53 and p21 were detected in SW480 cells were examined by Western blot . Results The plasmid of pcDNA 3. 12 PGDH was successfully established. After being t ransfected with this gene, the growth velocity of these t ransfected cells was significantly slower than the parental cell line. Colony formation activity of SW480/pcDNA 3. 12PGDH was 16 % while that of the cont rol cell was 58 % in six well plate ( P < 0. 05) . The activity of anchorage2independent proliferation of SW480/ pcDNA 3. 1 PGDH was lower than that of SW480/ pcDNA 3. 1 in soft agar. Otherwise, the expression of p53 and p21 were higher than cont rol. Conclusion PGDH could reduce the abilities of proliferation and of anchorage2independent proliferation of SW480 cells which is through p53 pathway possibility.
2008, 35(04): 240-243.
DOI: 10.3971/j.issn.1000-8578.2204
Abstract：
Objective To clone and express the human survivin gene in E.coli and prepare its antiserum. Methods The survivin cDNA was amplified from the total RNA of HL-60 cells by RT-PCR.the open reading form of survivin gene was inserted to the expression plasmid pET32 a(+),transfected into E.coil BL21(DE3)and induced with IPTG,the expressed protein was analyzed with SDS-PAGE.Then,the Balb/c mice were immunized with the purified expression protein,the antiserum titer was detected with ELISA,and the specificity was identified with Western blot and immunocytochemist ry techniques. Results DNA sequencing result s showed that survivin gene was exactly consistent with the sequence reported in Genbank, the survivin expressed in E. coli, the protein amounted to 30 % of total bacteria protein and the molecular weight was 37 KD. The titer of antiserum against recombinant surviving was 1∶1600, identified the recombinant protein in E. coli and the surviving in tumor cell specifically. Conclusion The survivin gene was cloned and expressed in E. coli, the antiserum against recombinant survivin was prepared and could be detect the target protein in tumor cell.
Objective To clone and express the human survivin gene in E.coli and prepare its antiserum. Methods The survivin cDNA was amplified from the total RNA of HL-60 cells by RT-PCR.the open reading form of survivin gene was inserted to the expression plasmid pET32 a(+),transfected into E.coil BL21(DE3)and induced with IPTG,the expressed protein was analyzed with SDS-PAGE.Then,the Balb/c mice were immunized with the purified expression protein,the antiserum titer was detected with ELISA,and the specificity was identified with Western blot and immunocytochemist ry techniques. Results DNA sequencing result s showed that survivin gene was exactly consistent with the sequence reported in Genbank, the survivin expressed in E. coli, the protein amounted to 30 % of total bacteria protein and the molecular weight was 37 KD. The titer of antiserum against recombinant surviving was 1∶1600, identified the recombinant protein in E. coli and the surviving in tumor cell specifically. Conclusion The survivin gene was cloned and expressed in E. coli, the antiserum against recombinant survivin was prepared and could be detect the target protein in tumor cell.
2008, 35(04): 243-246.
DOI: 10.3971/j.issn.1000-8578.2053
Abstract：
Objective To investigate the effect of all-trans rctinoic acid(ARTA) on XIAP-associated factor 1(XAF1) expression and the growth of human colorectal carcinoma. Methods Lovo cell were treated with various concentrations of ATRA.The mRNA and protein expression of XAF1 were det-ected by Western blot and RT-PCR methods.The cell growth was measured by MTT assay.Transcription activity of XAF1 promoter is examined by luciferase reporter assay. Results The mRNA and protein expression of XAF1 were up regulated by ATRA stimulation in a dose2dependent manner, MTT showed that ATRA could suppress the proliferation of colorectal carcinoma cells. ATRA stimulation also resulted in increase in luciferase activity in cells t ransfected with the pla-smid containing XAF1 promoter region sequences. Conclusion ARTA could significantly inhibit the growth of human color2ectal carcinoma cells, and this anti2tumor effect might be related to the up2regulation of XAF1 mRNA and protein by increasing the t ranscription activity of XAF1 promoter.
Objective To investigate the effect of all-trans rctinoic acid(ARTA) on XIAP-associated factor 1(XAF1) expression and the growth of human colorectal carcinoma. Methods Lovo cell were treated with various concentrations of ATRA.The mRNA and protein expression of XAF1 were det-ected by Western blot and RT-PCR methods.The cell growth was measured by MTT assay.Transcription activity of XAF1 promoter is examined by luciferase reporter assay. Results The mRNA and protein expression of XAF1 were up regulated by ATRA stimulation in a dose2dependent manner, MTT showed that ATRA could suppress the proliferation of colorectal carcinoma cells. ATRA stimulation also resulted in increase in luciferase activity in cells t ransfected with the pla-smid containing XAF1 promoter region sequences. Conclusion ARTA could significantly inhibit the growth of human color2ectal carcinoma cells, and this anti2tumor effect might be related to the up2regulation of XAF1 mRNA and protein by increasing the t ranscription activity of XAF1 promoter.
2008, 35(04): 247-250.
DOI: 10.3971/j.issn.1000-8578.1529
Abstract：
Objective To explore the mechanism of immune escape from natural killer(NK)cell-mediated immune surveillance of malignant gliomas. Methods We took K562 cells cytolysis sensitively to NK cell as positive control,cytotoxicities of NK cells isolated from 5 healthy volunteers against U251 cells were analyzed by LDH releasing assay at different effector-to-target cell ratios(E∶T).The genes and proteins expression of NKG2D ligands on K562 and U251 cell line were respectively measured by RT-PCR and flow cytometry.In blocking experiment s, mAbs of different N KG2D ligands and HLA2 Ⅰmolecules were added to the target cells at E∶T of 20∶1. Results Cytotoxicity of N K cells against K562 cells was much higher than that against U251 cells at the same ET ratio. There was a significant difference between them. The genes of N KG2D ligands were positive in K562 and U251 cells, All the proteins of N KG2D ligands were expressed on K562 cell surface, but noly ULBP2 molecule was found on U251 cell surface. In blocking experiment s, the cytotoxicity of N K cells against K562 cell was partially inhibited, that against U251 cell was not influenced when mAbs of different N KG2D ligands were added ; the cytotoxicity of N K cells against U251 cell was dramatically upgraded, that against K562 cell was not influenced when mAb of HLA2 Ⅰmolecules was added. Conclusion Aberrant expression of N KG2D ligand and high expression HLA2 Ⅰmolecules may cont ribute to immune escape f rom N K cell2mediated immune surveillance of malignant gliomas.
Objective To explore the mechanism of immune escape from natural killer(NK)cell-mediated immune surveillance of malignant gliomas. Methods We took K562 cells cytolysis sensitively to NK cell as positive control,cytotoxicities of NK cells isolated from 5 healthy volunteers against U251 cells were analyzed by LDH releasing assay at different effector-to-target cell ratios(E∶T).The genes and proteins expression of NKG2D ligands on K562 and U251 cell line were respectively measured by RT-PCR and flow cytometry.In blocking experiment s, mAbs of different N KG2D ligands and HLA2 Ⅰmolecules were added to the target cells at E∶T of 20∶1. Results Cytotoxicity of N K cells against K562 cells was much higher than that against U251 cells at the same ET ratio. There was a significant difference between them. The genes of N KG2D ligands were positive in K562 and U251 cells, All the proteins of N KG2D ligands were expressed on K562 cell surface, but noly ULBP2 molecule was found on U251 cell surface. In blocking experiment s, the cytotoxicity of N K cells against K562 cell was partially inhibited, that against U251 cell was not influenced when mAbs of different N KG2D ligands were added ; the cytotoxicity of N K cells against U251 cell was dramatically upgraded, that against K562 cell was not influenced when mAb of HLA2 Ⅰmolecules was added. Conclusion Aberrant expression of N KG2D ligand and high expression HLA2 Ⅰmolecules may cont ribute to immune escape f rom N K cell2mediated immune surveillance of malignant gliomas.
2008, 35(04): 251-254.
DOI: 10.3971/j.issn.1000-8578.692
Abstract：
Objective A novel Smac-mimic polypeptide(SmacN7) was designed and synthesized to study its biological activity that promotes apoptosis of bladder cancer cells. Methods SmacN7 was synthesized with aid of polypeptide solid phase synthesis technique,purified with reverse-phase HPLC and identified with mass spectrometry.Using fluorescent microscopy,MTT assay and flow cytometry,the apoptosis effect on bladder cancer T24 cell line with low-dosage of MMC was evaluated. Results The peptide was more than 95% in purity and the measured value of molecular weight was conformed to it s theoretical value. Typical apoptosis morphological changes of the cells were detected af ter being incubated by 50～500μg/ L SmacN7 for 12～48 h. With the increase of concent ration of SmacN7 or the prolongation of the t reating time, the proliferation inhibitory ratio of the cancer cells increased by (9. 62 ±1. 07) %～ (61. 48±1. 15) %、(24. 17 ±1. 02) %～ (72. 86 ±1. 68) %、(43. 24 ±1. 15) %～ (84. 91 ±1. 74) % and the percentage of apoptosis increased by (6. 12 ±1. 16) %～ (49. 81 ±2. 11) %、( 13. 47 ±1. 15) %～ ( 64. 54 ±2. 27) %、(28. 91 ±1. 08) %～ (82. 36 ±2. 15) % when t reated for 12 、24 、48 h respectively. Conclusion The collected fusion peptide SmacN7 is the target peptide with high purity and can be stably t ransferred into T24 cells and effectively utilized. It clearly has the biological activity in promoting apoptosis of bladder cancer T24 cell lines with the induction of low2dosage of MMC. These result s accumulate valuable data for the biological therapy of bladder cancer.
Objective A novel Smac-mimic polypeptide(SmacN7) was designed and synthesized to study its biological activity that promotes apoptosis of bladder cancer cells. Methods SmacN7 was synthesized with aid of polypeptide solid phase synthesis technique,purified with reverse-phase HPLC and identified with mass spectrometry.Using fluorescent microscopy,MTT assay and flow cytometry,the apoptosis effect on bladder cancer T24 cell line with low-dosage of MMC was evaluated. Results The peptide was more than 95% in purity and the measured value of molecular weight was conformed to it s theoretical value. Typical apoptosis morphological changes of the cells were detected af ter being incubated by 50～500μg/ L SmacN7 for 12～48 h. With the increase of concent ration of SmacN7 or the prolongation of the t reating time, the proliferation inhibitory ratio of the cancer cells increased by (9. 62 ±1. 07) %～ (61. 48±1. 15) %、(24. 17 ±1. 02) %～ (72. 86 ±1. 68) %、(43. 24 ±1. 15) %～ (84. 91 ±1. 74) % and the percentage of apoptosis increased by (6. 12 ±1. 16) %～ (49. 81 ±2. 11) %、( 13. 47 ±1. 15) %～ ( 64. 54 ±2. 27) %、(28. 91 ±1. 08) %～ (82. 36 ±2. 15) % when t reated for 12 、24 、48 h respectively. Conclusion The collected fusion peptide SmacN7 is the target peptide with high purity and can be stably t ransferred into T24 cells and effectively utilized. It clearly has the biological activity in promoting apoptosis of bladder cancer T24 cell lines with the induction of low2dosage of MMC. These result s accumulate valuable data for the biological therapy of bladder cancer.
2008, 35(04): 255-257.
DOI: 10.3971/j.issn.1000-8578.6
Abstract：
Objective To investigate the effect of the small interfering RNA(siRNA) targeted to survivin in combination with 5-Fu on inhibition the of MCF-7 cells proliferation. Methods A siRNA targeted to survivin was synthesized.siRNA was transfected into MCF-7 by lipofectin.Cell growth activity was evaluated by MTT assay.SAS software and Jin Zhenjun Method were used to evaluate the combination effects of siRNA and 5-Fu. Results Combination treatment with 5 nmol/L siRNA reduced the IC50 of 5-Fu from 4.42 μg/ml to 1.18 18μg/ ml ; the inhibitory of combination t reatment on MCF27 cells was higher than that of 5-Fu alone ( F = 26. 74, P < 0. 01. And synergism(Q ≥1. 15) was observed at the lower concent ration of 52Fu with combination of siRNA. Conclusion siRNA may enhance the effectiveness of 5-Fu on inhibiting the proliferation of MCF-7 cells.
Objective To investigate the effect of the small interfering RNA(siRNA) targeted to survivin in combination with 5-Fu on inhibition the of MCF-7 cells proliferation. Methods A siRNA targeted to survivin was synthesized.siRNA was transfected into MCF-7 by lipofectin.Cell growth activity was evaluated by MTT assay.SAS software and Jin Zhenjun Method were used to evaluate the combination effects of siRNA and 5-Fu. Results Combination treatment with 5 nmol/L siRNA reduced the IC50 of 5-Fu from 4.42 μg/ml to 1.18 18μg/ ml ; the inhibitory of combination t reatment on MCF27 cells was higher than that of 5-Fu alone ( F = 26. 74, P < 0. 01. And synergism(Q ≥1. 15) was observed at the lower concent ration of 52Fu with combination of siRNA. Conclusion siRNA may enhance the effectiveness of 5-Fu on inhibiting the proliferation of MCF-7 cells.
2008, 35(04): 258-262.
DOI: 10.3971/j.issn.1000-8578.2752
Abstract：
Objective To explore clinicopathologic features and epidermal growth factor receptor mutations associated with epithelial-mesenchymal transition in non-small cell lung cancer. Methods The status of epithelial-mesenchymal transition of 62 patients with surgically resected non-small cell lung cancer specimens were tested by immunohistochemical staining.The rate of tumor epithelial phenotype was calculated with stratification factors of clinicopathologic features and EGFR genotype.Statistical significance was assessed by chi2square test s and logistic regression. Results The overall f requency rate of epithelial phenotype among 62 NSCLC was 35. 48 % (22 of 62) . The f requency of epithelial phenotype ( E2cadherinpositive) was greater for EGFR mutant s versus wild types (77. 78 % versus 18. 18 %; P < 0. 0001) ;females patient s versus males patient s (54. 55 % versus 25 %; P = 0. 02) ;adenocarcinomas versus other histology (39. 47 % versus 29. 17 %; P = 0. 4087 ) ; never smokers versus ever smokers ( 42. 42 % versus 27. 59 %; P = 0. 2231) ;age < 60 year versus age ≥60 year (43. 33 % versus 28. 12 %; P = 0. 211) ; earlystage disease versus advanced disease (38. 24 % versus 32. 12 %; P = 0. 6178) . Conclusion The clinicopathologic features of patient s with lung cancer showing epithelial markers tend to be women, nonsmokers, adenocarcinoma and with EGFR mutation.
Objective To explore clinicopathologic features and epidermal growth factor receptor mutations associated with epithelial-mesenchymal transition in non-small cell lung cancer. Methods The status of epithelial-mesenchymal transition of 62 patients with surgically resected non-small cell lung cancer specimens were tested by immunohistochemical staining.The rate of tumor epithelial phenotype was calculated with stratification factors of clinicopathologic features and EGFR genotype.Statistical significance was assessed by chi2square test s and logistic regression. Results The overall f requency rate of epithelial phenotype among 62 NSCLC was 35. 48 % (22 of 62) . The f requency of epithelial phenotype ( E2cadherinpositive) was greater for EGFR mutant s versus wild types (77. 78 % versus 18. 18 %; P < 0. 0001) ;females patient s versus males patient s (54. 55 % versus 25 %; P = 0. 02) ;adenocarcinomas versus other histology (39. 47 % versus 29. 17 %; P = 0. 4087 ) ; never smokers versus ever smokers ( 42. 42 % versus 27. 59 %; P = 0. 2231) ;age < 60 year versus age ≥60 year (43. 33 % versus 28. 12 %; P = 0. 211) ; earlystage disease versus advanced disease (38. 24 % versus 32. 12 %; P = 0. 6178) . Conclusion The clinicopathologic features of patient s with lung cancer showing epithelial markers tend to be women, nonsmokers, adenocarcinoma and with EGFR mutation.
2008, 35(04): 263-265.
DOI: 10.3971/j.issn.1000-8578.2748
Abstract：
Objective To investigate the expression and clinical significance of Ang-2 and VEGF in human breast carcinoma. Methods The expression of Ang-2 and VEGF in 85 specimens of breast carcinoma and in 42 specimens of fibroadenoma of breast was examined by SABC immunohistochemical method,and the relationship between these two factors and the clinicopathological factors was evaluated. Results The positive rate of Ang-2 in breast carcinoma(68.24%,58/85) was significantly higher than that in fibroadenoma of breast(7.14%, 3/ 42 ) ( P < 0. 0001 ), and the positive rate of VEGF in breast carcinoma (57. 65 %, 49/ 85) was significantly higher than that in fibroadenoma of breast ( 4. 76 %, 2/ 42 ) ( P <0. 0001), too. The expression of Ang22 and VEGF were not associated with patient age and tumor size ( P > 0. 05) . The positive rate of VEGF in group of stage Ⅲand Ⅳ and lymph node2positive were significantly higher than that in group of stage Ⅰand Ⅱ and lymph node2negative respectively ( P < 0. 0001) . The positive rate of Ang22 in group of stage Ⅲand Ⅳwas significantly higher than that in group of stage Ⅰand Ⅱ ( P = 0. 015) . The positive rate of Ang22 in group of lymph node2positive was significantly higher than that in group of lymph node2negative ( P < 0. 0001) . There was a significantly correlation between the expression of Ang22 and VEGF. Conclusion There was an abnormal expression of Ang22 and VEGF in breast carcinoma, these two factors were associated with the prognosis of patient s.
Objective To investigate the expression and clinical significance of Ang-2 and VEGF in human breast carcinoma. Methods The expression of Ang-2 and VEGF in 85 specimens of breast carcinoma and in 42 specimens of fibroadenoma of breast was examined by SABC immunohistochemical method,and the relationship between these two factors and the clinicopathological factors was evaluated. Results The positive rate of Ang-2 in breast carcinoma(68.24%,58/85) was significantly higher than that in fibroadenoma of breast(7.14%, 3/ 42 ) ( P < 0. 0001 ), and the positive rate of VEGF in breast carcinoma (57. 65 %, 49/ 85) was significantly higher than that in fibroadenoma of breast ( 4. 76 %, 2/ 42 ) ( P <0. 0001), too. The expression of Ang22 and VEGF were not associated with patient age and tumor size ( P > 0. 05) . The positive rate of VEGF in group of stage Ⅲand Ⅳ and lymph node2positive were significantly higher than that in group of stage Ⅰand Ⅱ and lymph node2negative respectively ( P < 0. 0001) . The positive rate of Ang22 in group of stage Ⅲand Ⅳwas significantly higher than that in group of stage Ⅰand Ⅱ ( P = 0. 015) . The positive rate of Ang22 in group of lymph node2positive was significantly higher than that in group of lymph node2negative ( P < 0. 0001) . There was a significantly correlation between the expression of Ang22 and VEGF. Conclusion There was an abnormal expression of Ang22 and VEGF in breast carcinoma, these two factors were associated with the prognosis of patient s.
2008, 35(04): 266-268.
DOI: 10.3971/j.issn.1000-8578.1537
Abstract：
Objective To study immunohistochemical expression of Glut-1 and COX-2 in endometrial adenocarcinoma and precancerous lesion. Methods Immunohistochemical staining S-P method was used to detect the expression of Glut-1 and COX-2 in 20 cases of normal proliferative endometrium,23 cases of simple endometrial hyperplasia,21 cases of complex endometrial hyperplasia,43 cases of atypical endometrial hyperplasia,25 cases of endometrial adenocarcinoma. Results The positive expression rates of Glut-1 and COX-2 were 0% and 10. 0 % in normal proliferative endomet rium, 0 % and 9. 1 % in simple endomet rial hyperplasia, 4. 8 % and 14. 3 % in complex endomet rial hyperplasia, 20. 0 % and 25. 0 % in low2grade atypical endomet rial hyperplasia, 52. 2 % and 52. 4 % in high2grade atypical endomet rial hyperplasia, 88. 0 % and 91. 7 % in endomet rial adenocarcinoma. There were all significant difference between benign, hyperplastic and malignant endomet rial epithelia, the difference between endomet rial adenocarcinoma and high2grade atypical endomet rial hyperplasia were also statistically significant . Positive correlation was also found between COX22 and Glut21 expression ( P = 0. 000) . Conclusion Abnormal expression of Glut21 and COX22 may cont ribute to the pathogenesis and development of the endomet rical carcinoma, the combined use of Glut21 and COX22 is valuable in distinguishing endomet rial adenocarcinoma f rom endomet rial hyperplastic lesions.
Objective To study immunohistochemical expression of Glut-1 and COX-2 in endometrial adenocarcinoma and precancerous lesion. Methods Immunohistochemical staining S-P method was used to detect the expression of Glut-1 and COX-2 in 20 cases of normal proliferative endometrium,23 cases of simple endometrial hyperplasia,21 cases of complex endometrial hyperplasia,43 cases of atypical endometrial hyperplasia,25 cases of endometrial adenocarcinoma. Results The positive expression rates of Glut-1 and COX-2 were 0% and 10. 0 % in normal proliferative endomet rium, 0 % and 9. 1 % in simple endomet rial hyperplasia, 4. 8 % and 14. 3 % in complex endomet rial hyperplasia, 20. 0 % and 25. 0 % in low2grade atypical endomet rial hyperplasia, 52. 2 % and 52. 4 % in high2grade atypical endomet rial hyperplasia, 88. 0 % and 91. 7 % in endomet rial adenocarcinoma. There were all significant difference between benign, hyperplastic and malignant endomet rial epithelia, the difference between endomet rial adenocarcinoma and high2grade atypical endomet rial hyperplasia were also statistically significant . Positive correlation was also found between COX22 and Glut21 expression ( P = 0. 000) . Conclusion Abnormal expression of Glut21 and COX22 may cont ribute to the pathogenesis and development of the endomet rical carcinoma, the combined use of Glut21 and COX22 is valuable in distinguishing endomet rial adenocarcinoma f rom endomet rial hyperplastic lesions.
2008, 35(04): 269-271.
DOI: 10.3971/j.issn.1000-8578.2762
Abstract：
Objective To explore the possibility of sensing detection of thymidine kinase(TK) in sera as a clinical diagnostic indicator of tumor. Methods To detect the TK levels of different tumor serum samples by using amplified mass piezoelectric quartz crystal immunosensors. Results Liver cancer sera have the highest TK level(2.44±0.46 ng/mL),the galactophore sera take second place(1.16±0.24 ng/mL),and the TK levels of both cancer sera are distinctly different from that of the other malignant tumors(P<0.001).The TK levels of lung cancer sera, digestive system cancer sera, Genital system cancer sera and other malignant tumor sera are closely consistent and there is no distinct difference among them ( P > 0. 05), but there are distinctly different f rom that of the carcinoid sera ( P < 0. 001) . Moreover, the TK level of carcinoid sera is distinctly higher than that of normal human sera ( P < 0. 001) . Conclusion The amplified mass piezoelect ric quartz crystal immunosensors as a new sensitive quantitative method for TK in human sera has great potential for the clinical diagnosis of cancers and the distinguish of cancer types, especially for the clinic diagnoses of liver cancer and galactophore.
Objective To explore the possibility of sensing detection of thymidine kinase(TK) in sera as a clinical diagnostic indicator of tumor. Methods To detect the TK levels of different tumor serum samples by using amplified mass piezoelectric quartz crystal immunosensors. Results Liver cancer sera have the highest TK level(2.44±0.46 ng/mL),the galactophore sera take second place(1.16±0.24 ng/mL),and the TK levels of both cancer sera are distinctly different from that of the other malignant tumors(P<0.001).The TK levels of lung cancer sera, digestive system cancer sera, Genital system cancer sera and other malignant tumor sera are closely consistent and there is no distinct difference among them ( P > 0. 05), but there are distinctly different f rom that of the carcinoid sera ( P < 0. 001) . Moreover, the TK level of carcinoid sera is distinctly higher than that of normal human sera ( P < 0. 001) . Conclusion The amplified mass piezoelect ric quartz crystal immunosensors as a new sensitive quantitative method for TK in human sera has great potential for the clinical diagnosis of cancers and the distinguish of cancer types, especially for the clinic diagnoses of liver cancer and galactophore.
2008, 35(04): 272-274.
DOI: 10.3971/j.issn.1000-8578.2697
Abstract：
Objective To investigate the clinicopathologic features of patients with node-negative metastasis(pN0) colorectal cancer confirmed by routine pathologic examination(H﹠E staining),and their relationship with survival. Methods The clinico-pathologic data of 57 pN0 colorectal cancer patients were analyzed retrospectively.Kaplan-Meier method was used to compare the survival rate,and Cox proportional hazard model was used to assess the independent prognosis factors for pN0 colorectal cancer. Results Serosa of most cases was not involved and the proportion of localized and well2differentiated aden2 carcinoma was higher. The 52year survival rate was 83. 1 %. Conclusion Patient s with colorectal cancer without lymph node metastasis may have well prognosis since radical resection was performed. Invasive depth was the independent prognostic factor.
Objective To investigate the clinicopathologic features of patients with node-negative metastasis(pN0) colorectal cancer confirmed by routine pathologic examination(H﹠E staining),and their relationship with survival. Methods The clinico-pathologic data of 57 pN0 colorectal cancer patients were analyzed retrospectively.Kaplan-Meier method was used to compare the survival rate,and Cox proportional hazard model was used to assess the independent prognosis factors for pN0 colorectal cancer. Results Serosa of most cases was not involved and the proportion of localized and well2differentiated aden2 carcinoma was higher. The 52year survival rate was 83. 1 %. Conclusion Patient s with colorectal cancer without lymph node metastasis may have well prognosis since radical resection was performed. Invasive depth was the independent prognostic factor.
2008, 35(04): 275-277.
DOI: 10.3971/j.issn.1000-8578.1539
Abstract：
Objective The efficacy of high-dose therapy(HDT) with peripheral blood progenitor cell(PBPC) transplantation for patients with solid tumors remains undefined.An important prerequisite for this mode of therapy is a reliable methord of obtaining sufficient PBPCs to ensure rapid and durable engraftment while maintaining patients in at least a stable disease state at the time of commencing the high-dose phase of therapy.Docetaxel has an effective anti-tumour activity in mang solid tumors.The objective of our study is to explore the efficacy and safety of high2dose of docetaxel with granulocyte colony2stimulating factor ( G2CSF) for mobilization of peripheral blood stem cells. Methods The 30 patient s with malignant solid tumors were involved in our study. Docetaxel (120 mg/ m2 ) was given with a continuous int ravenous infusion for 3 hours on day 1. When the number of white blood cell was reached to 1. 0 ×109 / L, G2CSF 5μg/ kg was given twice a day by injection subcutaneous until the end of leukopheresis. Results The leukopheresis was started on average day 9. 97 ±1. 03 following docetaxel therapy, the mean number of CD34 + cells was 3. 49 ×106 / kg ( range 1. 71 ×106 / kg～16. 69 ×106 / kg), by two times per patient of leukopheresis. There are 25 cases whose number of CD34 + cells is more than 2. 0 ×106 / kg. The average day is (6. 47 ±1. 01) when the number of white blood cells was reduced to 1. 0 ×109 / L af ter docetaxel was given. The average duration is (3. 50 ±1. 01) days for G2CSF injection subcutaneous. No significant difference in number of CD34 + cells was found in different leukopheresis time. 6 cases had mild arthralgia, 3 cases had slight diarrhea, 1 cases had oropharyngeal mucositis. Conclusion Docetaxel (120 mg/m2 ) with G2CSF(5μg/ kg) is an effective and safety mobilizing regimen for autologous peripheral blood stem progenitor cells in patient s with malignant solid tumors.
Objective The efficacy of high-dose therapy(HDT) with peripheral blood progenitor cell(PBPC) transplantation for patients with solid tumors remains undefined.An important prerequisite for this mode of therapy is a reliable methord of obtaining sufficient PBPCs to ensure rapid and durable engraftment while maintaining patients in at least a stable disease state at the time of commencing the high-dose phase of therapy.Docetaxel has an effective anti-tumour activity in mang solid tumors.The objective of our study is to explore the efficacy and safety of high2dose of docetaxel with granulocyte colony2stimulating factor ( G2CSF) for mobilization of peripheral blood stem cells. Methods The 30 patient s with malignant solid tumors were involved in our study. Docetaxel (120 mg/ m2 ) was given with a continuous int ravenous infusion for 3 hours on day 1. When the number of white blood cell was reached to 1. 0 ×109 / L, G2CSF 5μg/ kg was given twice a day by injection subcutaneous until the end of leukopheresis. Results The leukopheresis was started on average day 9. 97 ±1. 03 following docetaxel therapy, the mean number of CD34 + cells was 3. 49 ×106 / kg ( range 1. 71 ×106 / kg～16. 69 ×106 / kg), by two times per patient of leukopheresis. There are 25 cases whose number of CD34 + cells is more than 2. 0 ×106 / kg. The average day is (6. 47 ±1. 01) when the number of white blood cells was reduced to 1. 0 ×109 / L af ter docetaxel was given. The average duration is (3. 50 ±1. 01) days for G2CSF injection subcutaneous. No significant difference in number of CD34 + cells was found in different leukopheresis time. 6 cases had mild arthralgia, 3 cases had slight diarrhea, 1 cases had oropharyngeal mucositis. Conclusion Docetaxel (120 mg/m2 ) with G2CSF(5μg/ kg) is an effective and safety mobilizing regimen for autologous peripheral blood stem progenitor cells in patient s with malignant solid tumors.
2008, 35(04): 278-281.
DOI: 10.3971/j.issn.1000-8578.2196
Abstract：
Objective To evaluate the toxicity and efficacy of combination chemotherapy with paclitaxel plus cisplatin and fluorouracil(PCF)in advanced gastric cancer. Methods Between 2002 and 2006,thirty-five advanced gastric cancer patients who received PCF regimen were analyzed retrospectively.The combination chemotherapy included paclitaxel 150 mg/m2 as 3 hours infusion on day 1,cisplatin 12 mg/m2/d on days 1 to 5 and 5-Fu 3 g/m2 over 120h infusion.The therapy repeated every 3 weeks. Results Fifteen local advanced gast ric cancer patient s received PCF regimen af ter operations. Median time to progression and overall survival time were 11. 0 months and 18. 6 months, respectively. Twenty patient s with metastatic gast ric cancer received PCF regimen as salvage therapy. Fif teen patient s were assessable. Complete response 0 (0), partial response 3 (20 %), stable disease 9 (60 %) and progressive disease 3 (20 %) . Median time to progression and overall survival time were 7. 0 months and 9. 0 months, respectively. Frequent grade 3/ 4 toxicity for PCF were :nausea 18. 1 %, neut ropenia 9. 4 % and fatigue 7. 9 %. Febrile neut ropenia occurred 9. 5 %. Conclusion The toxicity of PCF regimen was acceptable and the efficacy needed further evaluation.
Objective To evaluate the toxicity and efficacy of combination chemotherapy with paclitaxel plus cisplatin and fluorouracil(PCF)in advanced gastric cancer. Methods Between 2002 and 2006,thirty-five advanced gastric cancer patients who received PCF regimen were analyzed retrospectively.The combination chemotherapy included paclitaxel 150 mg/m2 as 3 hours infusion on day 1,cisplatin 12 mg/m2/d on days 1 to 5 and 5-Fu 3 g/m2 over 120h infusion.The therapy repeated every 3 weeks. Results Fifteen local advanced gast ric cancer patient s received PCF regimen af ter operations. Median time to progression and overall survival time were 11. 0 months and 18. 6 months, respectively. Twenty patient s with metastatic gast ric cancer received PCF regimen as salvage therapy. Fif teen patient s were assessable. Complete response 0 (0), partial response 3 (20 %), stable disease 9 (60 %) and progressive disease 3 (20 %) . Median time to progression and overall survival time were 7. 0 months and 9. 0 months, respectively. Frequent grade 3/ 4 toxicity for PCF were :nausea 18. 1 %, neut ropenia 9. 4 % and fatigue 7. 9 %. Febrile neut ropenia occurred 9. 5 %. Conclusion The toxicity of PCF regimen was acceptable and the efficacy needed further evaluation.
2008, 35(04): 282-283.
DOI: 10.3971/j.issn.1000-8578.3397
Abstract：
Objective To study the clinical efficacy and side effects of thalidomide in combination with dexamethasone,25 previously untreated patients with MM receiving the regimen were analyzed. Methods Thalidomide was given orally at an initial dose of 50 mg/d once per night,and then gradually increased to the maximum dose of 400 mg/d at a rate of 50 mg /d per week,according to individual tolerance.Dexamethasone was given at 40 mg/d either orally or intravenously on days 1～4,9～12 and days 17～20.Twenty-eight days a cycle, all patient s were t reated at least for 3 months. Results The overall efficacy of the 25 patient s involved in our research is 80 %, among which, 16 % achieved complete remission (CR) (4cases), 24 % achieved partial remission ( PR) (6cases), and 40 % had improvement, while 20 % had no effect (5cases) . The mainly side effect s include constipation, somnolence, edema etc. Conclusion The combination of thalidomide with dexamethasone was effective in patient s with newly diagnosed myeloma, with slight side effect s.
Objective To study the clinical efficacy and side effects of thalidomide in combination with dexamethasone,25 previously untreated patients with MM receiving the regimen were analyzed. Methods Thalidomide was given orally at an initial dose of 50 mg/d once per night,and then gradually increased to the maximum dose of 400 mg/d at a rate of 50 mg /d per week,according to individual tolerance.Dexamethasone was given at 40 mg/d either orally or intravenously on days 1～4,9～12 and days 17～20.Twenty-eight days a cycle, all patient s were t reated at least for 3 months. Results The overall efficacy of the 25 patient s involved in our research is 80 %, among which, 16 % achieved complete remission (CR) (4cases), 24 % achieved partial remission ( PR) (6cases), and 40 % had improvement, while 20 % had no effect (5cases) . The mainly side effect s include constipation, somnolence, edema etc. Conclusion The combination of thalidomide with dexamethasone was effective in patient s with newly diagnosed myeloma, with slight side effect s.
